Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Clinical
  • Published:

Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases volume 27, pages 393–403 (2024)Cite this article

Subjects

Abstract

Introduction

Androgen receptor targeted agents (ARTA) have increasingly been incorporated into treatment regimens for various stages of prostate cancer. Patients are living longer with prostate cancer, and thus have a higher cumulative exposure to the treatment and its accompanying side effects, especially those of cardiovascular disease. We aim to assess the differences in the incidence of cardiac-related adverse events after treatment of prostate cancer with ARTA versus placebo.

Methods

Three databases were thoroughly searched for relevant articles. The PICOS model was used to frame our clinical question, with which 2 independent authors went through several rounds of screening to select the final included studies. Meta-analysis was done using the Cochran-Mantel-Haenszel Method. Quality assessment was carried out with the Cochrane Risk of Bias tool RoB 2.

Results

The use of ARTA in prostate cancer increases the incidence of cardiac-related adverse events (RR: 1.56, 95% CI: 1.29–1.90, p < 0.00001), such as hypertension (RR: 1.69, 95% CI: 1.46–1.97, p < 0.00001), ischaemic heart disease (RR: 1.84, 95% CI: 1.36–2.50, p < 0.0001), and arrhythmia (RR: 1.38, 95% CI: 1.11–1.71, p = 0.004), although this did not manifest in an increased incidence of cardiac arrests/deaths (RR: 1.28, 95% CI: 0.87–1.88, p = 0.21).

Discussion

ARTA increases the risk of cardiac-related adverse events, hypertension, ischaemic heart disease and arrhythmia. Armed with this knowledge, we will be better poised to manage cardiac risks accordingly and involve a cardiologist as required when starting patients on ARTA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: PRISMA diagram.
Fig. 2: Quality assessment as per RoB 2.
Fig. 3: Forest plot of primary outcome.
Fig. 4: Forest plot of primary outcome.
Fig. 5: Forest plot of primary outcome.

Similar content being viewed by others

Data availability

Additional data is presented in the supplementary material. Further data is available on request.

Material availability

Additional data is presented in the supplementary material. Further data is available on request.

References

  1. International W Prostate cancer statistics London: World Cancer Research Fund International; 2022 [updated 23 March 2022. Available from: https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/.

  2. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700.

    Article  CAS  PubMed  Google Scholar 

  4. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021;154:138–46.

    Article  CAS  PubMed  Google Scholar 

  6. Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39:2294–303.

    Article  CAS  PubMed  Google Scholar 

  7. Weiner AA-OX, Li EV, Desai AS, Press DJ, Schaeffer EM. Cause of death during prostate cancer survivorship: a contemporary, US population-based analysis. Cancer. 2021;127:2895–904.

    Article  PubMed  Google Scholar 

  8. Guo Y, Dong X, Mao S, Yang F, Wang RA-O, Ma W, et al. Causes of death after prostate cancer diagnosis: a population-based study. Oxid Med Cell Longev. 2022;2022:8145173.

  9. Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, et al. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open. 2021;4:e2119568.

  10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–60.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.

    Article  PubMed  Google Scholar 

  14. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010;28:3448–56.

  15. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–66.

  16. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9:e107516.

  17. Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020;113:9–21.

    Article  PubMed  Google Scholar 

  18. Takov K, Wu J, Denvir MA, Smith LB, Hadoke PWF. The role of androgen receptors in atherosclerosis. Mol Cell Endocrinol. 2018;465:82–91.

  19. Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20:17–24.

  20. Conover MA-O, Weaver J, Fan B, Leitz G, Richarz U, Li Q, et al. Cardiovascular outcomes among patients with castration-resistant prostate cancer: a comparative safety study using US administrative claims data. Prostate. 2023;83:729–39.

  21. Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16:e645–e53.

    Article  PubMed  Google Scholar 

  22. Rizzo A, Merler S, Sorgentoni G, Oderda M, Mollica V, Gadaleta-Caldarola G, et al. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opin Drug Metab Toxicol. 2021;17:1237–43.

    Article  CAS  PubMed  Google Scholar 

  23. Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S. Abiraterone acetate in the treatment of prostate cancer. Cancer Biomed Pharmacother. 2018;101:211–18.

  24. Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020;78:347–57.

    Article  CAS  PubMed  Google Scholar 

  25. Zhu X, Wu S. Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis. Cancer Investig. 2019;37:478–88.

    Article  Google Scholar 

  26. Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, et al. Androgen receptor inhibitor treatments: cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol Oncol. 2021;39:52–62.

    Article  CAS  PubMed  Google Scholar 

  27. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–4.

    Article  CAS  PubMed  Google Scholar 

  29. Caffo O, Ortega C, Nole F, Gasparro D, Mucciarini C, Aieta M, et al. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. Eur J Cancer. 2021;155:56–63.

    Article  CAS  PubMed  Google Scholar 

  30. Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, et al. Orteronel switch maintenance therapy in metastatic castration-resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11). Prostate. 2016;76:1519–27.

  31. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl J Med. 2019;381:121–31.

    Article  CAS  PubMed  Google Scholar 

  32. Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, et al. Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone. Eur Urol. 2019;76:418–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015;33:723–31.

  34. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399:1695–707.

    Article  CAS  PubMed  Google Scholar 

  35. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.

    Article  CAS  PubMed  Google Scholar 

  36. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N. Engl J Med. 2020;383:1040–9.

    Article  CAS  PubMed  Google Scholar 

  37. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl J Med. 2017;377:338–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Merseburger AS, Attard G, Astrom L, Matveev VB, Bracarda S, Esen A, et al. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncol. 2022;23:1398–408.

    Article  CAS  PubMed  Google Scholar 

  39. Pu Y-S, Ahn H, Han W, Huang S-P, Wu H-C, Ma L, et al. Enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer: an Asian multiregional, randomized study. Adv Ther. 2022;39:2641–56.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.

    Article  CAS  PubMed  Google Scholar 

  41. Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16:338–48.

    Article  CAS  PubMed  Google Scholar 

  42. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl J Med. 2012;367:1187–97.

    Article  CAS  PubMed  Google Scholar 

  43. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl J Med. 2022;386:1132–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150–8.

    Article  CAS  PubMed  Google Scholar 

  45. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, et al. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naive prostate cancer. Eur J Cancer 2021;157:259–67.

    Article  CAS  PubMed  Google Scholar 

  46. Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl J Med. 2020;382:2197–206.

    Article  CAS  PubMed  Google Scholar 

  47. Sun Y, Zou Q, Sun Z, Li C, Du C, Chen Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 2016;23:404–11.

    Article  CAS  PubMed  Google Scholar 

  48. Ye D, Huang Y, Zhou F, Xie K, Matveev V, Li C, et al. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naive patients with mCRPC in China, Malaysia, Thailand and Russia. Asian J Urol. 2017;4:75–85.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, National University Hospital, National University Health System, Singapore, Singapore

    Chloe Shu Hui Ong, Yu Xi Terence Law, Lin Kyaw, Qi Yang Lim, Ho Yee Tiong & Edmund Chiong

  2. Division of Urology, Ng Teng Fong General Hospital, National University Health System, Singapore, Singapore

    Tim Loke

  3. Raffles Urology Centre, Raffles Hospital, Singapore, Singapore

    Qing Hui Wu

  4. Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Edmund Chiong

Authors
  1. Chloe Shu Hui Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Xi Terence Law
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Kyaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qi Yang Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tim Loke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qing Hui Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ho Yee Tiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Edmund Chiong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CSHO conceived of and designed the meta-analysis, carried out data acquisition and analysis, and drafted and revised the manuscript. YXTL conceived of and designed the meta-analysis, carried out data acquisition and analysis, and drafted the manuscript. LK designed the meta-analysis, carried out data acquisition and analysis, and drafted the manuscript. QYL carried out data acquisition and analysis and drafted the manuscript. TL, QHW, HYT and EC participated in data analysis, revised the manuscript, and supervised the study. All authors read and approved the final manuscript and agree to be accountable for its publication.

Corresponding author

Correspondence to Chloe Shu Hui Ong.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ong, C.S.H., Law, Y.X.T., Kyaw, L. et al. Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 27, 393–403 (2024). https://doi.org/10.1038/s41391-024-00792-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-024-00792-5

Search

Advanced search

Quick links